Develops roluperidone to treat negative symptoms in people with schizophrenia and other drug candidates for central nervous system diseases.
10-K for FY2025, filed Mar 11, 2026
10-Q for Q3 FY2026, filed Nov 6, 2026
$100.7MView ↗
Competes with GlaxoSmithKline, Sanofi-Aventis, Janssen, Novartis, AstraZeneca, Eli Lilly, Bristol-Myers Squibb, Intra-Cellular Therapies, Karuna Therapeutics, Acadia Pharmaceuticals, Lundbeck, Reviva Pharmaceuticals, SyneuRx, Neurocrine, and Denovo Biopharma
10-K for FY2025, filed Mar 11, 2026Current drug therapies for the treatment of schizophrenia mainly target the positive symptoms of the disease. When patients present…View ↗
Loading...